We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
-$215M
Cap. Flow %
-11.22%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Sector Composition

Rank Sector Weight
1 Healthcare 12.85%
2 Industrials 0.12%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.06%
5 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CBMX
276
DELISTED
CombiMatrix Corporation
CBMX
$41K ﹤0.01%
+14,391
New +$45.7K
PVCT
277
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$35K ﹤0.01%
93,283
-632,917
-87% -$241K
INFI
278
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$30K ﹤0.01%
+22,500
New +$105K
INFI
279
PUT
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$30K ﹤0.01%
+225
New +$1.05K
INFI
280
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$22K ﹤0.01%
+167
New +$781
IPCI
281
PUT
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$19K ﹤0.01%
12
SVRA icon
282
PUT
Savara
SVRA
$1.09B
$17K ﹤0.01%
+5
New +$123
EYEGW
283
DELISTED
Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
$2K ﹤0.01%
53,893
-11,500
-18% -$8.15K
ACAD icon
284
Acadia Pharmaceuticals
ACAD
$4.45B
-46,258
Closed -$1.55M
ADVM
285
CALL
DELISTED
Adverum Biotechnologies
ADVM
-11
Closed -$55K
ALDX icon
286
Aldeyra Therapeutics
ALDX
$95.3M
-41,096
Closed -$172K
ALKS icon
287
Alkermes
ALKS
$8.47B
-15,000
Closed -$619K
AMRN
288
Amarin Corp
AMRN
$293M
-43,540
Closed -$1.64M
ARDX icon
289
Ardelyx
ARDX
$1.26B
-22,278
Closed -$173K
ASRT
290
DELISTED
Assertio
ASRT
-1,768
Closed -$1.93M
BCLI
291
CALL
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
-12
Closed -$47K
BHC icon
292
CALL
Bausch Health
BHC
$1.69B
-149
Closed -$392K
BMY icon
293
CALL
Bristol-Myers Squibb
BMY
$130B
-264
Closed -$1.69M
BPMC
294
CALL
DELISTED
Blueprint Medicines
BPMC
-3,000
Closed -$5.42M
BPMC
295
DELISTED
Blueprint Medicines
BPMC
-29,624
Closed -$535K
CARM
296
DELISTED
Carisma Therapeutics
CARM
-60,699
Closed -$387K
CLRB icon
297
Cellectar Biosciences
CLRB
$20M
-24
Closed -$242K
CRDF icon
298
Cardiff Oncology
CRDF
$63.6M
-1,181
Closed -$395K
BGMS
299
Bio Green Med Solution Inc
BGMS
$4.94M
-2
Closed -$628K
CYTK icon
300
CALL
Cytokinetics
CYTK
$10.8B
-1,066
Closed -$752K

Similar funds

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.